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Abstract
γ‐Aminobutyric acid type A (GABAA) receptors containing the α6 subunit are located 
in trigeminal ganglia, and their reduction by small interfering RNA increases inflamma-
tory temporomandibular and myofascial pain in rats. We thus hypothesized that enhanc-
ing their activity may help in neuropathic syndromes originating from the trigeminal 
system. Here, we performed a detailed electrophysiological and pharmacokinetic analy-
sis of two recently developed deuterated structurally similar pyrazoloquinolinone com-
pounds. DK‐I‐56‐1 at concentrations below 1 µM enhanced γ‐aminobutyric acid 
(GABA) currents at recombinant rat α6β3γ2, α6β3δ and α6β3 receptors, whereas it was 
inactive at most GABAA receptor subtypes containing other α subunits. DK‐I‐87‐1 at 
concentrations below 1 µM was inactive at α6‐containing receptors and only weakly 
modulated other GABAA receptors investigated. Both plasma and brain tissue kinetics 
of DK‐I‐56‐1 were relatively slow, with half‐lives of 6 and 13 hr, respectively, enabling 
the persistence of estimated free brain concentrations in the range 10–300 nM through-
out a 24‐hr period. Results obtained in two protocols of chronic constriction injury of the 
infraorbital nerve in rats dosed intraperitoneally with DK‐I‐56‐1 during 14 days after 
surgery or with DK‐I‐56‐1 or DK‐I‐87‐1 during 14 days after trigeminal neuropathy 
were already established, demonstrated that DK‐I‐56‐1 but not DK‐I‐87‐1 significantly 
reduced the hypersensitivity response to von Frey filaments.
Significance: Neuropathic pain induced by trigeminal nerve damage is poorly con-
trolled by current treatments. DK‐I‐56‐1 that positively modulates α6 GABAA recep-
tors is appropriate for repeated administration and thus may represent a novel treatment 
option against the development and maintenance of trigeminal neuropathic pain.
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1 |  BACKGROUND
Trigeminal neuropathic pain is a continuous and burning pain 
that involves the orofacial region, and is accompanied by 
paroxysms that can be instantly provoked by touch or other 
mild stimuli. It is commonly induced by a direct trauma of 
the trigeminal nerve and thus is also known as painful trau-
matic trigeminal neuropathy (Napeñas & Zakrzewska, 2011). 
Treatment of trigeminal neuropathy relies on off‐label drug 
use (Benoliel, Kahn, & Eliav, 2012; Benoliel, Teich, & Eliav, 
2016). However, in a recent open study only 11% of patients 
with painful traumatic trigeminal neuropathy had significant 
pain reduction in response to the available pharmacother-
apy (Haviv, Zadik, Sharav, & Benoliel, 2014). Thus, there 
is a clinical need for new treatment options for trigeminal 
neuropathy.
γ‐Aminobutyric acid type A (GABAA) receptors are 
GABA‐gated chloride channels composed of five protein 
subunits that belong to eight different subunit classes with 19 
distinct subunits (6α, 3β, 3γ, δ, ε, π, θ, 3ρ). Most GABAA re-
ceptors are composed of two α, two β and one γ2 subunit. The 
classical benzodiazepines allosterically modulate GABA‐in-
duced currents at αβγ2 receptors containing α1, α2, α3 or α5, 
but not α4 or α6 subunits (Olsen & Sieghart, 2008). Positive 
allosteric modulators (PAMs) that preferentially modulate 
α2βγ2 GABAA receptor subtypes are able to elicit a systemic 
analgesic effect (Knabl et al., 2008; Rudolph & Knoflach, 
2011). However, it is questionable to what extent it is possible 
to separate the antihyperalgesic actions of α2‐receptor‐pre-
ferring benzodiazepine‐like compounds from their potential 
to induce sedation (Ralvenius et al., 2016).
GABAA receptors containing the α6 subunit are abundant 
populations of inhibitory receptors in the cerebellar and co-
chlear nucleus granule cells and are also present in the olfac-
tory bulb, spinal cord and retina (Gutiérrez, Khan, & Blas, 
1996; Pirker, Schwarzer, Wieselthaler, Sieghart, & Sperk, 
2000; Wisden, Laurie, Monyer, & Seeburg, 1992). In addi-
tion, they have been identified in two major types of cells in 
the trigeminal ganglia (TG), namely in neurons and satellite 
glia (Hayasaki et al., 2006; Puri et al., 2012). Reducing α6 ex-
pression by infusing small interfering RNA into TG increased 
nociceptive responses in myofascial pain and inflammatory 
temporomandibular joint pain models (Kramer & Bellinger, 
2013; Puri et al., 2012). We therefore hypothesized that pos-
itive modulation of α6‐containing receptors may influence 
trigeminal neuropathic pain.
Pyrazoloquinolinones have been investigated as potential 
anxiolytics with an exceptionally low liability for sedative‐
like effects (Williams et al., 1989). Recently, pyrazoloquin-
olinones with specific substitution patterns were identified 
as the first ligands functionally selective for α6β2/3γ2 recep-
tors; one of them was PZ‐II‐029 (presented as compound 6 
in Varagic et al., 2013). Furthermore, LAU165, an inactive 
compound with similar chemical properties, was also identi-
fied (Treven et al., 2018).
To investigate whether positive modulation of α6‐con-
taining receptors may reduce trigeminal neuropathic pain, 
here we used two recently published deuterated, and thus 
metabolically more stable, pyrazoloquinolinone compounds: 
the PZ‐II‐029 analogue DK‐I‐56 and the LAU165 analogue 
DK‐I‐87‐1 (presented as 8b and 8 m, respectively, in Knutson 
et al., 2018). DK‐I‐87‐1 was inactive, while DK‐I‐56‐1 inhib-
ited the development and reduced the established trigeminal 
neuropathic pain in a rat model of chronic constriction injury 
of the infraorbital branch of the trigeminal nerve (Deseure & 
Hans, 2015).
2 |  METHODS
2.1 | Ligands
DK‐I‐56‐1 (7‐methoxy‐2‐(4‐(methoxy‐d3)phenyl)‐2,5‐di-
hydro‐3H‐pyrazolo[4,3‐c]quinolin‐3‐one) and DK‐I‐87‐1 
(8‐chloro‐2‐(2‐(methoxy‐d3)phenyl)‐2,5‐dihydro‐3H‐
pyrazolo[4,3‐c]quinolin‐3‐one) were synthesized at the 
Department of Chemistry and Biochemistry, University of 
Wisconsin—Milwaukee, USA (Knutson et al., 2018). For 
stock solutions, compounds were dissolved in 100% DMSO.
2.2 | Two‐electrode voltage clamp 
electrophysiology
Preparation of mRNA for rat α1, α2, α3, α4, α5, α6, β3, γ2 
and δ subunits and electrophysiological experiments with 
Xenopus laevis oocytes were performed as described previ-
ously (Forkuo et al., 2016). Mature female Xenopus laevis 
(Nasco, Fort Atkinson, WI, USA) were anaesthetized in a 
bath of ice‐cold 0.17% tricaine (Ethyl‐m‐aminobenzoate, 
Sigma‐Aldrich, St. Louis, MO, USA) before decapitation and 
transfer of the frog's ovary to ND96 medium (96 mM NaCl, 
2 mM KCl, 1 mM MgCl2, 5 mM HEPES; pH 7.5), in full 
accordance with the rules of the Austrian animal protection 
law. Following incubation in 1 mg/ml collagenase (Sigma‐
Aldrich, St. Louis, MO, USA) for 30 min, stage 5–6 oocytes 
were singled out of the ovary and defolliculated using a plati-
num wire loop or glass Pasteur pipette. Oocytes were stored 
and incubated at 18°C in NDE medium (96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2; pH 7.5) 
that was supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2.5 mM pyruvate. Oocytes were injected 
with an aqueous solution of mRNA. A total of 2.5 ng of 
mRNA per oocyte was injected. Subunit ratio was 1:1:5 for 
αxβ3γ2 (x = 1, 2, 3, 5), 3:1:5 for α4/α6β3γ2 and α6β3δ, and 
1:1 for α6β3 receptors. Injected oocytes were incubated for 
at least 36 hr before electrophysiological recordings. Oocytes 
were placed on a nylon grid in a bath of NDE medium. For 
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current measurements, oocytes were impaled with two mi-
croelectrodes, which were filled with 2 M KCl and had a 
resistance of 2–3 MΩ. The oocytes were constantly washed 
by a flow of 6 ml/min NDE that could be switched to NDE 
containing GABA and/or drugs. Drugs were diluted into 
NDE from DMSO solutions resulting in a final concentration 
of 0.1% DMSO. To test for modulation of GABA‐induced 
currents by compounds, a GABA concentration was titrated 
to trigger a specific fraction X of the respective maximum 
GABA‐elicited current of the individual oocyte (ECX, e.g. 
EC3–6 or EC90) and was applied to the cell together with 
various concentrations of tested compounds. All recordings 
were performed at room temperature at a holding potential 
of −60 mV using a Warner OC‐725C two‐electrode volt-
age clamp (TEV) (Warner Instrument, Hamden, CT, USA) 
or a Dagan CA‐1B Oocyte Clamp or a Dagan TEV‐200A 
TEV amplifier (Dagan Corporation, Minneapolis, MN, 
USA). Data were digitized using a Digidata 1322A or 1550 
data acquisition system (Axon Instruments, Union City, CA, 
USA), recorded using Clampex 10.5 software (Molecular 
Devices, Sunnyvale, CA, USA) and analysed using Clampfit 
10.5 and GraphPad Prism 6.0 software (La Jolla, CA, USA). 
Concentration–response data were fitted using the Hill equa-
tion. Data are given as mean ± SEM from at least three oo-
cytes of two batches.
2.3 | In vivo studies
2.3.1 | Animals and preparation
Experiments were carried out on eight‐week‐old male 
outbred Wistar albino rats weighing 160–180 g at arrival 
(88 rats for the neuropathic pain model and 60 for phar-
macokinetic studies), supplied by Military Farm, Belgrade, 
Serbia. Animals were housed individually, except for phar-
macokinetic studies (3–4 per cage), in Makrolon type III 
cages and had free access to food and water. The tempera-
ture of the animal room was 22 ± 1°C, relative humidity 
40%–70% and illumination 120 lx, with a 12‐hr light/dark 
cycle (lights on at 06:00 hr). All experiments took place 
during the light phase of the diurnal cycle (09:00–16:00 hr). 
All procedures were conducted according to the National 
Institutes of Health Animal Care and Use Committee 
guidelines and were approved by the Ethical Committee 
on Animal Experimentation of the Faculty of Pharmacy in 
Belgrade. Throughout the study, only experimentally naïve 
animals were used.
In a procedure slightly modified from Đorđević et al. 
(2015), biocompatible nanoemulsions of DK‐I‐56‐1 and 
DK‐I‐87‐1 were prepared by high‐pressure homogenization 
at 50°C to a compound concentration of 2 mg/ml. They were 
composed of 13.33% medium‐chain triglycerides, 6.67% 
castor oil, 2% soybean lecithin, 0.03% sodium oleate, 2% 
polyoxyethylensorbitanmonooleate, 0.05% butylhydroxytol-
uene, 2% DMSO and 73.67% ultrapure water.
2.4 | Pharmacokinetic studies
A detailed description of pharmacokinetic studies in rats is 
given in the Supporting Information Appendix S1. The stud-
ies with DK‐I‐56‐1 included assessment of pharmacokinetic 
behaviour of 2, 5, 10 and 20 mg/kg doses measured one hour 
after application (in order to choose the dose for repeated‐
dose studies), determination of the plasma and brain phar-
macokinetic profile after a single 10 mg/kg dose measured 
at various time points after application, and measurement 
of plasma and brain concentrations after six or eleven daily 
doses of 10 mg/kg DK‐I‐56‐1. In the latter case, the measure-
ments were performed 20 min and 24 hr after the final dose. 
Due to the ethical constraints of performing an elaborate 
analysis of a compound expected to be biologically inactive, 
the pharmacokinetic studies with DK‐I‐87‐1 were carried out 
only with the 10 mg/kg dose (demonstrated to be devoid of 
behavioural effects in Knutson et al., 2018). In a separate in 
vitro experiment, the rapid equilibrium dialysis assay was 
used to determine the free fraction of DK‐I‐56‐1 in rat plasma 
and brain tissue (Obradović et al., 2014).
2.5 | Chronic constriction injury of 
infraorbital nerve (IoN‐CCI)
The unilateral ligation of the infraorbital nerve (IoN) as 
an animal model of neuropathic pain was validated by 
Vos, Strassman, & Maciewicz, 1994. The present study 
was performed in a randomized and blinded manner. Rats 
were anaesthetized intraperitoneally with a combination 
of ketamine and xylazine (60 mg/kg + 10 mg/kg). A mid-
line scalp incision was made exposing skull and nasal 
bone. The infraorbital part of the IoN was exposed using 
a surgical procedure similar to that described by Deseure 
& Hans, 2015 and Vos et al., 1994. Specifically, the edge 
of the orbit, formed by the maxillary, frontal, lacrimal 
and zygomatic bones, was uncovered and the IoN was 
dissected free at its most rostral extent in the orbital cav-
ity, just caudal to the infraorbital foramen. Two chromic 
catgut ligatures (5–0) were loosely tied around the IoN 
(2 mm apart). To obtain the desired degree of constric-
tion, a criterion proposed by Bennett and Xie (1988) was 
applied. The ligatures reduced the diameter of the nerve 
by a just noticeable amount and retarded, but did not in-
terrupt the circulation through the superficial vasculature. 
The scalp incision was closed using silk sutures (5–0), 
and the rat was allowed to recover. In sham‐operated rats, 
the IoN was exposed using the same procedure, but it was 
not ligated. To minimize variability, all surgeries were 
performed by a single investigator.
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2.6 | Study design
In Experiment 1 (Figure 3a), rats (n = 46) were randomly 
assigned to one of the four groups: rats subjected to IoN 
surgery and treated with DK‐I‐56‐1, rats subjected to IoN 
surgery and treated with placebo, sham‐operated rats treated 
with DK‐I‐56‐1 and sham‐operated rats treated with placebo. 
For studying the effects of subchronic prophylactic treatment 
with the nanoemulsion formulation of DK‐I‐56‐1 in IoN‐CCI 
rats, DK‐I‐56‐1 (10 mg/kg) or its vehicle (placebo nanoemul-
sion) was injected i.p. daily, for 14 consecutive days start-
ing one day after surgery. Sham‐operated rats were treated 
in parallel.
In Experiment 2 (Figure 3a), all rats (n = 42) were sub-
jected to IoN surgery. After assessment of the neuropathy 
on day 14 (the criterion of increased response score to von 
Frey filament stimulation compared to baseline value), the 
animals that met the criterion were randomly assigned to 
one of the three groups: DK‐I‐56‐1, DK‐I‐87‐1 or placebo. 
The respective treatment was administered i.p. once daily for 
14 days, starting on day 15. In both experiments, treatment 
was administered at 3:00 p.m., up to 6 hr after finishing the 
behavioural testing (9:00–12:00 a.m.) or handling/habitua-
tion for the given day.
2.7 | Mechanical stimulation testing
After arrival, rats were acclimated to the housing facility for 
two days prior to subjecting to habituation to the test pro-
cedure. Rats were transported from the housing room to 
the test room (1‐min trip) and placed into transparent glass 
cages (L × W × H: 250 × 150 × 165 mm) with a metal lid. 
Habituation and testing were conducted in a darkened room 
(indirect white neon tubes fixed on the wall), with no back-
ground noise. Rats were habituated to von Frey filaments 
every day for 15 min, starting seven days before baseline data 
were obtained until the end of the experiment. Every 30 s, the 
researcher opened the lid and gently touched the wall of the 
cage with a plastic rod.
In Experiment 1, the response scores to the application 
of a graded series of three von Frey filaments in ascending 
order (1, 2 and 6 g) (Aesthesio® von Frey Kit, Touch‐Test 
Sensory Evaluator, Ugo Basile, Varese, Italy) onto the ipsi-
lateral vibrissal pad were measured one day before surgery 
(“pre”) and 7, 14, 21 and 28 days after IoN‐CCI. Each an-
imal was stimulated 3–5 times per filament to determine 
the response score for all three filaments. The response was 
categorized as score 0 (a complete lack of response), 1 (a 
stimulus detection), 2 (a withdrawal reaction), 3 (an escape/
attack response) or 4 (asymmetric face grooming) (Vos et al., 
1994). This categorization is widely used and accepted in the 
field. The grooming signed as four does not represent any 
regular grooming behaviour expected from the animals, but 
a series of three or more asymmetric grooming movements 
towards the injured region, and was validated as a reliable 
and specific measure of nociceptive response (Vos, Hans, & 
Adriaensen, 1998). For each rat, the mean of the assessed re-
sponse to three filaments was calculated as the score used in 
statistical analysis (Deseure, Koek, Adriaensen, & Colpaert, 
2003). Lower scores indicated a weak responsiveness to me-
chanical stimulation, while higher scores indicated a strong, 
hypersensitivity responsiveness. The criterion for exclusion 
of animals from statistical analyses was predefined for IoN‐
CCI–placebo group (consistently decreased reactivity in 
post‐surgery period when compared to baseline values), and 
for sham–placebo group (consistently increased reactivity in 
post‐surgery period when compared to the baseline values, 
the mean difference being more than or equal to 1.25 score 
points). The animals treated with DK‐I‐56‐1 could not have 
been excluded.
Throughout Experiment 2, a slightly different series of von 
Frey filaments (0.6, 1.4 and 4 g) was applied to the ipsilateral 
vibrissal pad. Since the number of disposable filaments was 
limited, it was decided in advance to choose two series of 
similar filaments in ascending order to be used in Experiment 
1 and Experiment 2. The response data were obtained one 
day before surgery (“pre”) and 7, 14, 21, 28 and 35 days after 
surgery; the latter three measurements were conducted only 
in those animals that met the criterion of neuropathy on day 
14 and were, thus, subjected to treatment. The scoring system 
used to assess the rat's reaction to the stimulus was the same 
as described above.
2.8 | Face grooming recordings
In Experiment 1, face grooming as a spontaneous activity was 
recorded. Face grooming during body grooming represents 
a reliable ethological measure to control for possible non‐
specific treatment effects, such as sedation or motor impair-
ment (Deseure & Hans, 2015). Behaviour was videotaped for 
10 min two days before surgery and 2, 4, 8 and 15 days after 
surgery (i.e. approximately 18 hr after 1, 3, 7 and 14 applica-
tions of treatment). The amount of time spent on face groom-
ing was determined using a stopwatch. Videotaped behaviour 
was analysed by two experimenters who were blind to the 
experimental group of rats.
2.9 | Statistical analysis
All data are expressed as mean ± SEM. Pharmacokinetic 
parameters were calculated using PK Functions for 
Microsoft Excel software (by Joel Usansky, Atul Desai and 
Diane Tang‐Liuwere). In Experiments 1 and 2, von Frey 
response score data were analysed using one‐way analysis 
of variance (ANOVA) for the given day, with treatment 
as between‐subject factor. Post hoc comparisons, where 
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applicable, were performed using SNK test. The paramet-
ric analysis of the response to von Frey filaments, as an 
ordinal variable, was well validated as statistically accept-
able and provides improved coherence between the statis-
tical output and graphical representation of data obtained 
in IoN‐CCI (Deseure et al., 2003). Face grooming during 
body grooming data in Experiment 1 were analysed non‐
parametrically (Kruskal–Wallis test and Friedman test). 
Differences were considered significant when p < 0.05. 
Statistical analysis was performed using SigmaPlot 11 
software (Systat Software Inc., Richmond, USA).
3 |  RESULTS
3.1 | In vitro activity of DK‐I‐56‐1 and 
DK‐I‐87‐1 on GABAA receptors
In a set of experiments with a panel of subunit combina-
tions expressed in X. laevis oocytes, we extended our in-
vestigation (Knutson et al., 2018) of the α6‐selectivity of 
DK‐I‐56‐1 and DK‐I‐87‐1 to eight GABAA receptor sub-
types, and confirmed the GABAA receptor subtype selec-
tivity of DK‐I‐56‐1, the deuterated version of PZ‐II‐029. 
In the panel of receptors investigated, we did not only in-
clude α6β3δ, but also the binary α6β3 receptors, because 
the latter receptors likely represent a fraction of receptors 
in oocytes, possibly contaminating current measurements 
at ternary receptors, and because they conceivably could 
also be present in TG. While α6β3γ2‐injected oocytes have 
highly variable GABAmax currents (Figure 1b), α6β3‐ and 
α6β3δ‐injected oocytes display more homogenous charac-
teristics. However, GABA‐induced currents of these recep-
tors were quite low, likely due to the fact that GABA is a 
partial agonist at these receptors (Sieghart & Savić, 2018). 
Variability in the maximum currents results from a variabil-
ity of the total number of receptors formed as well as from 
a variability of the receptor composition in the oocytes, de-
spite tightly controlled expression conditions. A variable 
extent of α6β3 receptors formed in α6β3γ2‐injected oo-
cytes thus causes a larger variability in the maximum cur-
rent than in α6β3δ‐injected oocytes. In α6β3γ2, DK‐I‐56‐1 
induced a left shift of the GABA concentration–response 
curve, thus increasing GABA potency, and a weak increase 
in the maximal GABA‐induced currents (data shown in 
Supporting Information Figure S1a). Due to the very low 
GABA‐induced currents in α6β3‐ and α6β3δ‐injected 
F I G U R E  1  (a) Concentration–response curves of the modulation of GABA EC3–6 (100%) currents by increasing concentrations of PZ‐
II‐029 and DK‐I‐56–1 in the α6β3γ2 receptor. Concentration–response curves for PZ‐II‐029 were taken from Varagic et al. (2013). Other receptor 
subtypes were investigated only at 1 and 10 µM DK‐I‐56‐1, because this compound did not significantly modulate GABA EC3–6 at these receptors 
below 1 μM concentration. (b) Currents elicited by 1 mM GABA in α6β3γ2‐, α6β3δ‐ and α6β3‐injected oocytes. (c) Representative traces of the 
cells expressing α6β3γ2, α6β3δ and α6β3 receptors, while applying GABA at a fixed concentration (0.3 μM for α6β3γ2, 10 μM for α6β3 and 
100 μM for α6β3δ) and an increasing concentration of DK‐I‐56‐1. The traces are scaled to display the reference traces (GABA alone at EC3–6 
for α6β3γ2 receptor and ~EC90 for α6β3δ‐ and α6β3‐injected cells) at the same size (see panel 1B for the current levels of the respective subunit 
combinations) so that the modulatory efficacy can be readily compared. (D) Screening receptor subtypes for modulatory effects of DK‐I‐87‐1. Bars 
per subunit combination represent compound concentrations of 1 and 10 µM, respectively. Data are presented relative to reference currents elicited 
by GABA alone (~ GABA EC3‐6 for all αβ3γ2 receptors, ~ EC90 for α6β3δ receptors)
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oocytes, currents could not be measured at GABA EC3–6. 
However, in both α6β3 and α6β3δ receptors, DK‐I‐56‐1 
did not change potency but enhanced GABA efficacy only, 
but to a much stronger extent than at α6β3γ2 receptors 
(see Supporting Information Figure S1c,b, respectively). 
It was thus possible to assess the modulation of α6β3 and 
α6β3δ receptors at GABA EC90. Recently summarized 
evidence indicated that at the upper limit of the estimated 
extrasynaptic GABA concentration in the brain (2.5 μM), 
the GABA‐induced currents of the highly GABA‐sensitive 
α6β3δ (and, if they exist physiologically, α6β3) recep-
tors are 80% of their respective maximal GABA‐induced 
currents and above (Mortensen, Patel, & Smart, 2012; 
Sieghart & Savić, 2018). Measuring the effects of drugs 
at GABA EC90 at these receptors is thus physiologically 
relevant. Supporting Information Figure S1d exemplifies 
the currents elicited by various GABA concentrations at 
the three GABAA receptor subtypes.
We confirmed that PZ‐II‐029 and DK‐I‐56‐1 have compa-
rable receptor subtype selectivity. Both compounds did not or 
only weakly modulated GABA‐induced currents at αxβ3γ2 
GABAA receptors containing α1, α2, α3, α4 or α5 subunits 
below 1 µM concentration (Figure 1a and Varagic et al., 
2013) but substantially enhanced GABA‐induced chloride 
flux at α6β3γ2, α6β3δ or α6β3 receptors (Figure 1a,c) already 
at sub‐µM or low µM concentrations. Within methodological 
precision, and as expected, the deuterated analogue behaves 
pharmacologically as the parent compound. Example current 
recordings for α6β3γ2, α6β3δ or α6β3 receptors are shown in 
Figure 1c and in Supporting Information Figure S1. In con-
trast to DK‐I‐56‐1, DK‐I‐87‐1 did not significantly modulate 
GABA‐induced currents at α6 receptors and only weakly 
modulated other receptor subtypes investigated at 1 µM con-
centration (Figure 1d). It thus represents an appropriate con-
trol compound for behavioural studies.
3.2 | Pharmacokinetic studies
The concentration–time profiles of DK‐I‐56‐1 in rat plasma 
and brain following intraperitoneal administration of a 
10 mg/kg dose in the nanoemulsion, with the calculated 
pharmacokinetic parameters, were similar to those given in 
Knutson et al. (2018) that were obtained with a suspension 
formulation, and given in Supporting Information Figure S2. 
The kinetic curves of DK‐I‐56‐1, with maximum concentra-
tions above 10 µM in plasma and above 1 µM in brain, con-
firmed its ability to be absorbed and distributed in brain, as 
previously demonstrated (Knutson et al., 2018). Both plasma 
and brain tissue kinetics were relatively slow with half‐lives 
being approximately 6 and 13 hr, respectively. While the free 
fraction of DK‐I‐56‐1 determined by rapid equilibrium dialy-
sis in blood was exceptionally low (below the limit of quan-
tification), the free fraction in brain tissue equalled 19.45%.
The concentrations of DK‐I‐56‐1 in rat plasma and brain 
tissue 1 hr following i.p. administration of Wisden 2, 5, 10 
and 20 mg/kg doses are shown in Supporting Information 
Table S1. The 10 mg/kg dose resulted in concentrations 
in plasma and brain in the micromolar, or close to micro-
molar range, respectively, and was thus selected for fur-
ther study. Supporting Information Table S1 also shows 
the concentrations in plasma and brain obtained following 
subacute (6 days) or subchronic (11 days) DK‐I‐56‐1 dos-
ing. The concentrations attainable in repeated‐dose studies 
were in general agreement with those expected on the basis 
of the pharmacokinetic profile presented in Supporting 
Information Figure S2, meaning that administration of 
multiple doses of DK‐I‐56‐1 may only result in slight quan-
titative changes in elimination pathways, and enabling the 
persistence of estimated free brain concentrations in the 
minimum to maximum range 10–300 nM throughout the 
24‐hr period.
The results presented in Supporting Information Table S2 
show an exceptionally stable plasma level that is maintained 
at about 1 µM as long as 24 hr following the last repeated 
dose of DK‐I‐87‐1. On the contrary, the concentrations ob-
tainable in brain tissue were relatively low in general and 
particularly low following 11 doses, suggesting that some 
qualitative changes, possibly in brain permeability and/or 
metabolism, occurred during repeated dosing.
3.3 | Behavioural studies
3.3.1 | Experiment 1: Prophylactic 
antinociceptive effect of DK‐I‐56‐1 in the 
neuropathic pain model
In this experiment, animals were treated either with daily 
injections of 10 mg/kg DK‐I‐56‐1 or placebo on days 1 to 
14 after surgery, or sham surgery, respectively, to assess 
a prophylactic effect of the pyrazoloquinolinone ligand 
on the development of neuropathic pain (the hypersensi-
tivity response). Figure 2a summarizes the timeline of the 
experiment.
The results of the assessment of the hypersensitivity 
response in Experiment 1 are summarized in Figure 2b 
(response score to von Frey filament stimulation for all 
four groups, measurements were performed in steady 
state before the next injection of drug or placebo). Three 
rats were not included in statistical analysis due to ex-
clusion criteria; all raw data are presented in Supporting 
Information Table S3.
As shown in Figure 2b, basal response scores (“pre”) were 
similar among all four groups (F(3,39) = 1.72; p = 0.18); 
moreover, the scores of the two IoN‐CCI groups (at about 
1.7 points) were virtually identical. Although the response to 
von Frey filaments in the IoN‐CCI–placebo group assessed 
   | 979VASOVIĆ et Al.
seven days after surgery reached a 2.4 score points, overall 
statistical difference among the four groups was not found at 
this time point (F(3,39) = 1.67; p = 0.19).
Significant differences between the four groups on 
post‐operative days 14 (F(3,39) = 3.2; p < 0.05), 21 
(F(3,39) = 5.07; p < 0.05) and 28 (F(3,39) = 5.24; 
p < 0.05) were revealed by one‐way ANOVA applied on 
the response scores. Post hoc tests demonstrated signifi-
cant differences between IoN‐CCI–placebo and sham–pla-
cebo groups on all three time points, suggesting that the 
performed IoN‐CCI induced a consistent neuropathic‐like 
response. Post hoc comparisons also showed that repeated 
treatment with DK‐I‐56‐1 can provide a preventive effect 
on the development of neuropathic pain, based on a sig-
nificant difference between IoN‐CCI–DK‐I‐56‐1 and IoN‐
CCI–placebo groups on post‐operative days 14 and 21. 
On post‐operative day 28, i.e. 14 days after the last dose 
of DK‐I‐56‐1, the significance of the effect of DK‐I‐56‐1 
disappeared. Thus, DK‐I‐56‐1 demonstrated a capability 
to suppress the development of neuropathic pain related to 
the constriction of branches of the trigeminal nerve during 
treatment administration and for seven days after discon-
tinuing treatment.
The results of the assessment of face grooming during 
body grooming, as a physiological manifestation of the 
rat's behaviour on which IoN‐CCI is expected to have lit-
tle or no effect, are summarized in Figure 2c. The level of 
activity was distinct on each of the five days monitored, 
and no significant differences among groups were detected. 
This parameter, characterized by a substantial variability, 
demonstrated the lack of sedation‐like or motor‐impairing 
influences of DK‐I‐56‐1, at least at the time of behavioural 
testing.
3.3.2 | Experiment 2: Therapeutic effect of 
DK‐I‐56‐1 in the neuropathic pain model
The affirmative results of Experiment 1 ethically justified the 
use, in the next experiment, of a suitable compound of the 
same chemotype (DK‐I‐87‐1) as a negative control for the 
α6 GABAA receptor‐mediated mechanism(s). In this experi-
ment, animals were treated with daily injections of 10 mg/
kg DK‐I‐56–1, or 10 mg/kg DK‐I‐87‐1, or placebo, on days 
15 to 28 after surgery, respectively, to assess a therapeutic 
effect of the pyrazoloquinolinone ligands on the fully devel-
oped neuropathic hypersensitivity. Figure 3a summarizes the 
timeline of the experiment.
Among the tested animals, five rats were not included 
in statistical analysis due to exclusion criteria, while one 
rat was highly aggressive from the beginning of treatment 
F I G U R E  2  (a) Treatment group timeline of Experiment 1. (b) 
Response score to von Frey filament stimulation for all four groups. 
Response to the application of a graded series of three von Frey 
filaments onto ipsilateral (left) vibrissal pad of IoN‐CCI and sham‐
operated animals was measured one day before surgery (pre) and on 
post‐operative days 7, 14, 21 and 28. Treatment (10 mg/kg DK‐I‐56‐1 
or placebo) was administered during 14 days, started one day after 
operation. Experimental groups: IoN‐CCI–DK‐I‐56‐1, IoN‐CCI–
placebo, sham–DK‐I‐56‐1 and sham–placebo consisted of 12, 11, 11 
and 9 animals, respectively. Values are presented as mean ± SEM. 
Data were analysed using one‐way ANOVA and SNK post hoc test. 
Significant differences versus placebo are indicated by * = p < 0.05. 
(c) Face grooming during body grooming recordings were taken two 
days before surgery (pre) and 2, 4, 8 and 15 days after surgery. See b 
for treatment groups. Values are presented as mean ± SEM
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and was hence discontinued; all raw data are presented in 
Supporting Information Table S4. Similar to Experiment 
1, IoN‐CCI resulted in a mean response score of about 2.5 
on post‐operative day 14 (Figure 3b). One‐way ANOVA 
showed a significant difference between groups on days 
21 (F(2,33) = 3.50; p < 0.05) and 28 (F(2,33) = 4,84; 
p < 0.05), but not on day 35 (F(2,33) = 1,22; p = 0.31). 
Post hoc tests revealed that repeated doses of DK‐I‐56‐1 
from day 15 to day 28 resulted on days 21 and 28 in a statis-
tically significant decrease in von Frey scores when com-
pared to rats treated with placebo. The rats treated with 
DK‐I‐87‐1 did not differ significantly compared to either 
placebo‐ or DK‐I‐56‐1‐treated rats.
4 |  DISCUSSION
Chronic constriction injury of the infraorbital branch of the 
trigeminal nerve (IoN‐CCI), with elicited hyperresponsive-
ness to mechanical stimulation of the whisker pad skin (i.e. 
hypersensitivity, cf. Hansson & Bouhassira, 2015) that is 
not accompanied by a latency or refractory period, has been 
validated as a model of trigeminal neuropathic pain (Deseure 
& Hans, 2015; Iwata, Imamura, Honda, & Shinoda, 2011). 
Using this model, we tested the hypothesis that positive 
modulation of α6‐containing receptors with an appropriate li-
gand recently discovered by our group (Knutson et al., 2018) 
may prevent the development and/or suppress maintenance 
F I G U R E  3  (a) Treatment group timeline. (b) Response score to von Frey filament stimulation for three groups. Response to the application 
of a graded series of three von Frey filaments onto ipsilateral (left) vibrissal pad of IoN‐CCI animals was measured one day before surgery (pre) 
and on post‐operative days 14, 21, 28 and 35. Treatment (DK‐I‐56‐1, DK‐I‐87‐1 or placebo) was administered after assessment of mechanical 
hypersensitivity on day 15. Animals were treated during 14 consecutive days. Twelve animals were in each treatment group (DK‐I‐56‐1, DK‐I‐87‐1 
and placebo). Values are presented as mean ± SEM. Data were analysed using one‐way ANOVA and SNK post hoc test. Significant differences 
versus placebo are indicated by * = p < 0.05
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of trigeminal neuropathic pain. Both parts of the hypothesis 
were confirmed with a 10 mg/kg dose of DK‐I‐56‐1 that was 
repeatedly administered throughout the first or the second 
14‐day period after surgery and thus during development or 
maintenance of neuropathic pain, respectively (Deseure & 
Hans, 2015). Notably, the 10 mg/kg dose of DK‐I‐56‐1 did 
neither acutely affect anxiety level, muscle strength and basic 
sensorimotor capabilities of rats as assessed in the elevated 
plus maze, grip strength test and cued water‐maze training, 
respectively (Knutson et al., 2018), nor affect, in the present 
experiment 1 of its repeated administration, face grooming 
during body grooming, as a part of general body grooming 
behaviour, non‐specific to pain (Deseure & Hans, 2015).
Effect of DK‐I‐56‐1 treatment on neuropathic pain devel-
opment could still be observed at day 21, and thus, 7 days 
after treatment was terminated, but not thereafter. Analogous 
results were presented for a selective agonist at 5‐HT1A re-
ceptors, in a similar IoN‐CCI protocol (Deseure et al., 2003). 
In the experiment investigating the effect of DK‐I‐56‐1 on 
already established neuropathic pain, treatment effects were 
present after 6 as well 13 daily doses, and declined within 
one week afterwards. The effects are thus not prolonged, but 
determined by its plasma or brain levels that fade away after 
treatment termination. The prolonged effect in the first ex-
periment might then have reflected the time needed for the 
pathological process to flare up after initial suppression by 
treatment. It must be emphasized that, in contrast to previ-
ous studies with other compounds (Deseure et al., 2003; Gris 
et al., 2016; Michot, Bourgoin, Viguier, Hamon, & Kayser, 
2012), the actions of DK‐I‐56‐1, DK‐I‐87‐1 or placebo on the 
development or maintenance of neuropathic pain were inves-
tigated under steady‐state conditions. In this vein, mild hyper-
locomotion noticed in both rats and mice acutely treated with 
DK‐I‐56‐1 but not with DK‐I‐87‐1 (Knutson et al., 2018), 
while reflecting a subtle increase in motivational drive possi-
bly applicable in depressive conditions (Bewernick, Urbach, 
Broder, Kayser, & Schlaepfer, 2017), could not have affected 
behavioural measurements in the present study.
The α6 subunit has been most extensively studied in the 
cerebellum, where it is known to form synaptic α6β3γ2 re-
ceptors and extrasynaptic α6β3γ2 and α6β3δ receptors 
(Jechlinger, Pelz, Tretter, Klausberger, & Sieghart, 1998; 
Nusser, Sieghart, & Somogyi, 1998). In TG, immunohisto-
chemical studies in 2‐ to 3‐week‐old rats indicated that the 
majority of neurons express α1, α3, α4, α5, β2/3 and γ1‐3 
subunits in their cell bodies, whereas α6 and δ subunits 
were detected only in cell bodies of a subset of small neu-
rons (Hayasaki et al., 2006). However, in a subsequent im-
munofluorescent study performed in adult rats (Puri et al., 
2012), 86%, 74% and 74%, of all small, medium and large 
TG neurons, respectively, expressed α6‐containing GABAA 
receptors. Age differences in the animals investigated might 
have contributed to the different abundance of α6‐containing 
GABAA receptors in these studies. The subunit composition 
of α6‐containing GABAA receptors within the TG neurons 
is currently unclear, but both α6β2/3γ2 and α6β2/3δ recep-
tors might be present in these neurons (Hayasaki et al., 2006). 
The present electrophysiological analysis demonstrated that 
in contrast to DK‐I‐87‐1, that is inactive at α6‐receptors 
and slightly active at some of the other GABAA receptors at 
1 µM concentrations, DK‐I‐56‐1 concentration‐dependently 
enhances the action of GABA at α6β3γ2, α6β3δ and α6β3 
receptors at 0.1 µM and above, but requires concentrations 
of 1 µM and above for starting the modulation of most of the 
other GABAA receptor subtypes investigated. The functional 
selectivity of DK‐I‐56‐1 for α6‐containing receptors is further 
accentuated by the low‐to‐moderate free brain concentrations 
(10–300 nM) achieved by this compound, as indicated in the 
present and a previous study (Knutson et al., 2018). Such 
concentrations do not allow modulation of GABA‐induced 
currents of other GABAA receptor subtypes possibly present 
at the TG neurons.
Rapid firing of TG neurons mediates neuropathic pain 
evoked by the IoN‐CCI protocol (Vos et al., 1994). Although 
cell bodies of mammalian sensory ganglia are generally 
devoid of synaptic contacts, exogenous GABA can induce 
Cl‐ currents in all TG neurons examined. Thus, all GABAA 
receptors present at these cell bodies are extrasynaptic 
(Hayasaki et al., 2006). In TG, GABA is synthesized and re-
leased by 70% of all neurons, but can be accumulated only by 
their surrounding satellite cells. It has been hypothesized that 
frequently firing sensory neurons can lead to elevated extra-
cellular K+ concentrations during repolarization after action 
potentials, which might induce GABA release from satellite 
cells and/or neurons, providing an inhibitory feedback to 
sensory neurons (Hayasaki et al., 2006). Subsequent activa-
tion of the highly GABA‐sensitive α6‐containing receptors 
(Karim et al., 2013; Mortensen et al., 2012) on the cell bodies 
of TG neurons might then have inhibited the firing of the re-
spective TG neurons and thus also the synaptic transmission 
at the central terminals of the trigeminal nucleus caudalis. 
DK‐I‐56‐1 might have enhanced the effect of endogenous 
GABA and by that sufficiently reduced synaptic transmission 
at the respective terminals of the trigeminal nucleus caudalis 
to suppress pain perception.
Kinetic profiles of DK‐I‐56‐1 and DK‐I‐87‐1, formu-
lated into biocompatible nanoemulsions with high content 
of water, were sufficiently slow that even once‐daily dosing 
has been appropriate for reaching effective concentrations 
during most of the inter‐dose interval. In particular, incorpo-
ration of 20% of oil phase in the nanoemulsion formulation 
of DK‐I‐56‐1 was shown to result in substantial (threefold vs. 
intravenous, and fivefold vs. intraperitoneal route) increase 
in the brain half‐life when compared to the suspension for-
mulation (Knutson et al., 2018), which is concordant with the 
formulation effects previously seen with diazepam (Đorđević 
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et al., 2015). Remarkably, the free DK‐I‐56‐1 concentration 
in plasma was extremely low and non‐calculable but still 
resulted in significant concentrations of the compound in 
the brain. Due to the lipophilicity of DK‐I‐56‐1, brain up-
take presumably was unimpaired. A similar observation, that 
brain uptake is not markedly influenced by low free plasma 
fraction of a ligand, has been made with a series of lipo-
philic N‐benzyl‐substituted phenethylamines (Ettrup et al., 
2011). Interestingly, the trigeminal ganglion not only is rich 
in lipids, but also is located outside the blood–brain barrier 
(Eftekhari et al., 2015). However, the pharmacological tar-
gets of DK‐I‐56‐1 may also be located more rostrally, such as 
in the synaptic terminals of α6‐containing TG neurons in the 
spinal trigeminal subnucleus caudalis, or anywhere else in 
the trigeminal pain pathway, and thus behind the blood–brain 
barrier (Shibuta et al., 2012). Independently of where the α6‐
containing receptors are located that mediate the effects of 
DK‐I‐56‐1, its pharmacologically effective concentration is 
expected to be related to the brain concentration; namely, it 
has recently been demonstrated that the unbound fraction in 
brain tissue homogenates of a set of several low molecular 
weight drugs highly correlates with that in the dorsal root 
ganglion, which can be taken as a more general surrogate for 
the situation in peripheral nerve tissue (Liu et al., 2018).
Although DK‐I‐56‐1 is a highly selective positive 
modulator of α6‐containing GABAA receptors, we can-
not exclude alternative sites of action of this compound, 
which is a clear limitation of the present study; namely, 
its action might also be in part mediated by interactions 
with some of the high‐affinity benzodiazepine binding 
site subtypes of GABAA receptors (Hulse et al., 2015), at 
which DK‐I‐56‐1 acts as a high‐affinity, electrophysiolog-
ically silent ligand (functional benzodiazepine antagonist; 
Knutson et al., 2018; Varagic et al., 2013). Furthermore, 
although it has been demonstrated that DK‐I‐56‐1 dis-
played negligible displacement in a panel of radioligand 
binding assays for 46 receptors, transporters and channels, 
except for the benzodiazepine site of GABAA receptors 
and very weak binding at 5‐HT7 and μ‐opioid receptors 
(Knutson et al., 2018), we also cannot exclude a possible 
functional modulation by this ligand of these and other 
targets. To investigate whether the effects of DK‐I‐56‐1 
on neuropathic pain could be blocked by an antagonist 
at the proposed site of its action, the α6+β3‐ interface of 
GABAA receptors would be the method of choice to con-
firm its site of action. Unfortunately, such an antagonist 
currently is not available (Sieghart & Savić, 2018). The 
competitive non‐selective GABA site antagonist bicuc-
ulline was sometimes used intrathecally or intradermally 
in acute pain models (e.g. Nadeson & Goodchild, 2000; 
Pathirathna et al., 2005) to probe for the involvement of 
GABAergic neurotransmission. In our chronic pain model, 
continuous intrathecal infusion of bicuculline would be 
required to block the action of DK‐I‐56‐1 under steady‐
state conditions. However, this would result in a complex, 
unpredictable outcome, including the possible expression 
of the proconvulsant properties of bicuculline. Further ex-
periments will thus have to be performed to identify the 
actual target of action of DK‐I‐56‐1 against neuropathic 
orofacial pain and its location in the peripheral or central 
part of the trigeminal system.
In summary, we demonstrated that DK‐I‐56‐1, a function-
ally selective PAM at GABAA receptors containing the α6 
subunit, significantly reduced both the development and the 
maintenance of trigeminal neuropathic pain. These effects 
were assessed in the steady state and thereby were devoid 
of any behaviourally non‐specific influences. These data for 
the first time demonstrate that positive modulators of α6‐con-
taining GABAA receptors might represent a mechanistically 
novel treatment option for trigeminal neuropathic pain, with 
promising potential for clinical development, as underlined 
by their lack of benzodiazepine‐like pharmacological proper-
ties (Knutson et al., 2018).
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